Business Wire

YOKOGAWA-ELECTRIC

15.2.2024 03:01:28 CET | Business Wire | Press release

Share
Yokogawa Provides Remote Operation/Monitoring System and Video Monitoring Solution for Japan’s Largest Wind Farm

Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Solution Service Corporation has completed the design, supply, and commissioning of a remote operation and monitoring system based on the OpreX™ Collaborative Information Server for the offshore wind turbines and onshore facilities at the Ishikari Bay New Port Offshore Wind Farm. The company has also contracted to provide maintenance services at this wind farm, which is operated by JERA Co., Inc. and the Green Power Investment Corporation and owned through Green Power Ishikari GK, a special-purpose corporation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213110562/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ishikari Bay New Port Offshore Wind Farm (Source: Green Power Investment Corporation)

The Ishikari Bay New Port Offshore Wind Farm is the first wind farm in Japan to use large-scale 8,000kW wind turbines, and as of the start of commercial operations on January 1, 2024, it is the largest commercial wind farm in Japan. The remote operation and monitoring system supplied by Yokogawa includes a video system for the monitoring of all the offshore and onshore wind power generating facilities at this wind farm. On an ongoing basis, the company will also provide maintenance services for these systems.

At the core of this remote operation and monitoring system is Yokogawa’s Collaborative Information Server, a solution that offers centralized management of data from the offshore wind turbines, the transformer substation’s large-scale storage batteries, and cameras installed on the wind turbines and storage batteries, and in the turbine maintenance yard. This video monitoring system utilizes the Edge Gateway AG 10 (for indoor) solution provided by Yokogawa subsidiary amnimo Inc.

Wind is a renewable energy source, and the amount of electricity produced varies depending on weather conditions. Taking into account information on power demand provided by the transmission system operator, this remote operation and monitoring system provides the data required to control the amount of power that will be stored by the storage battery system.

In addition to the systems delivered for this project, Yokogawa Solution Service has also received orders from Green Power Investment Corporation for systems that will aggregate information in real-time from wind farms all around Japan, and link this with cloud-based analysis tools. And together with Green Power Investment, Yokogawa Solution Service has commenced proof-of-concept tests in which the DTSX3000 optical fiber temperature sensor, a product in the OpreX Field Instruments lineup, is utilized to detect signs of damage to the submarine cables at the Ishikari Bay New Port Offshore Wind Farm.

Yokogawa is firmly focused on developing the system of systems (SoS) concept, whereby systems work together as a whole while maintaining operational and management independence to achieve, in an emergent way, goals that cannot be achieved independently. While there are many types of equipment and system configurations at wind farms, Yokogawa possesses the operational technology (OT) know-how needed to interpret data from sensors and other devices and thereby identify how the equipment and systems should be linked to achieve optimization at the individual and collective levels. By leveraging this know-how to provide solutions that cover everything from operation to overall system maintenance, Yokogawa will contribute to the realization of a decarbonized society.

About Yokogawa

Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 129 companies spanning 60 countries.
For more information, visit www.yokogawa.com

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, or their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213110562/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye